Background: SARS-CoV-2 enters the body through inhalation or self-inoculation to mucosal surfaces. The kinetics of the ocular and nasal mucosal-specific-immunoglobulin A(IgA) responses remain under-studied. Methods: Conjunctival fluid (CF, n = 140) and nasal epithelial lining fluid (NELF, n = 424) obtained by paper strips and plasma (n = 153) were collected longitudinally from SARS-CoV-2 paediatric (n = 34) and adult (n = 47) patients. The SARS-CoV-2 spike protein 1(S1)-specific mucosal antibody levels in COVID-19 patients, from hospital admission to six months post-diagnosis, were assessed. Results: The mucosal antibody was IgA-predominant. In the NELF of asymptomatic paediatric patients, S1-specific IgA was induced as early as the first four days post-diagnosis. Their plasma S1-specific IgG levels were higher than in symptomatic patients in the second week after diagnosis. The IgA and IgG levels correlated positively with the surrogate neutralization readout. The detectable NELF “receptor-blocking” S1-specific IgA in the first week after diagnosis correlated with a rapid decline in viral load. Conclusions: Early and intense nasal S1-specific IgA levels link to a rapid decrease in viral load. Our results provide insights into the role of mucosal immunity in SARS-CoV-2 exposure and protection. There may be a role of NELF IgA in the screening and diagnosis of SARS-CoV-2 infection.
There are no gold standards for diagnosing atopy. Skin prick test (SPT) is used to identify allergens while serum immunoglobulin (Ig) E can be a sign of acute allergic reaction. Yet, the latter might not provide specific associations to the intensity of allergic symptoms but a parasite infection. Moreover, these tests involve unpleasant sensations. With the nasal strip method developed to collect nasal epithelial lining fluid (NELF), we explore its role in allergy research. We hypothesized that local mucosal IgE and mediators are higher in patients with airway allergy and the levels of such might directly reflect the intensity of allergic symptoms. Patients were recruited in the allergy clinic. Severity score of allergic rhinitis, asthma, and eczema were graded by two allergists while atopic and food allergy status were indicated by SPT. Total IgE and cytokines in NELF were measured by ELISA and Cytometric Bead Array respectively. Serum IgE levels were retrieved from clinical records. Correlation was tested using Spearman’s test. 36 patients (5-41 years old) were recruited. Mucosal and serum IgE were correlated (r=0.60, p=0.02). A negative correlation between age and mucosal IgE was observed (r=-0.43, p=0.01). Mucosal IgE level was not correlated with the number of respiratory and food allergens and allergic diseases severity. Surprisingly, mucosal IgE had a positive correlation with eczema severity (r=0.54, p=0.001) but not asthma severity. IL-6 level was detectable in 8 subjects but IL-17A, IFN-γ, IL-10, IL-4, IL-2 were undetectable. NELF provides rich information of local immunity and reflects serum IgE levels. Its correlation with eczema severity requires further investigation.
SARS-CoV-2 (SCoV-2) has caused worldwide pandemic for more than a year. Its transmission is yet under control as most infected people show mild flu-like illness or are asymptomatic. Respiratory samples screening for SCoV-2 nuclei acid is utilized to identify active cases while the serological detection of SCoV-2 specific immunoglobulin (Ig) represents exposure to SCoV-2. The nasal mucosa is the infection site and the nasal epithelial lining fluid (NELF) contains virus and reflects its immunological profile. We collected NELF using nasal strips from 82 SCoV-2 infected subjects on disease confirmation, day 7, 14, 21, 28, 3 and 6 months after. NELF was eluted (Chan, RWY et al. J Infect 2020) and subjected to viral gene quantification and anti-SCoV-2 IgA measurement by ELISA. The clinical lab data showed that the viral load lasted for 7.5day(d) in children and 9.3d in adult. 94% of patients who took the serological test showed positive IgG results on 12d (median) after diagnosis. 19 subjects were followed for >3 months for their SCoV-2 IgA level in NELF. The 1st detection was 5d (median) post-diagnosis, which is earlier than the serological IgG. NELF IgA lasted for 92d and peaked on 13d post-diagnosis with different magnitudes. Here, we demonstrated that collecting NELF by nasal strip as a self-administered and non-invasive tool for the surveillance of active and convalescent cases. J Infect doi: 10.1016/j.jinf.2020.11.009
Background Immunity acquired from natural SARS-CoV-2 infection and vaccine wanes overtime. This longitudinal prospective study compared the effect of a booster vaccine (BNT162b2) in inducing the mucosal (nasal) and serological antibody between Covid-19 recovered patients and healthy unexposed subjects with two dose of mRNA vaccine (vaccine-only group). Method Eleven recovered patients and eleven gender-and-age matched unexposed subjects who had mRNA vaccines were recruited. The SARS-CoV-2 spike 1 (S1) protein specific IgA, IgG and the ACE2 binding inhibition to the ancestral SARS-CoV-2 and omicron (BA.1) variant receptor binding domain were measured in their nasal epithelial lining fluid and plasma. Result In the recovered group, the booster expanded the nasal IgA dominancy inherited from natural infection to IgA and IgG. They also had a higher S1-specific nasal and plasma IgA and IgG levels with a better inhibition against the omicron BA.1 variant and ancestral SARS-CoV-2 when compared with vaccine-only subjects. The nasal S1-specific IgA induced by natural infection lasted longer than those induced by vaccines while the plasma antibodies of both groups maintained at a high level for at least 21 weeks after booster. Conclusion The booster benefited all subjects to obtain neutralizing antibody (NAb) against omicron BA.1 variant in plasma while only the Covid-19 recovered subjects had an extra enrichment in nasal NAb against Omicron BA.1 variant.
Background: While rhinoviruses (RVs) typically cause mild respiratory infections, their persistence during the SARS-CoV-2 pandemic, particularly in Hong Kong’s strict zero-coronavirus disease 2019 policy, revealed unexpected epidemiological patterns. Two distinct RV surges emerged despite stringent public health measures, suggesting unique transmission advantages among circulating strains. We hypothesised that RV persistence during pandemic restrictions reflected strain-specific adaptations in respiratory tract replication efficiency and/or immune evasion. Methods: We analysed RV genotypes and conducted blinded clinical severity assessment for 96 paediatric hospitalisations during 2020–2021 outbreaks, compared with 180 age- and sex-matched control subjects from the corresponding weeks in pre-pandemic years (2018–2019). RV isolates from 2020 to 2021 outbreaks were characterised for their replication competence and transcriptomic responses in primary human nasal epithelial cell (HNEC) and environmental stability assays, using RV-A16 and RV-A1B as controls. Result: Minor group genotypes RV-A47 and RV-A49 were overrepresented during these two outbreaks. RV-A49 exhibited comparable replication efficiency to RV-A16 but induced significantly stronger transcriptomic responses, notably enhanced TNF and IL-1 signalling, in HNECs, alongside robust replication competence. Our data also suggests the association of RV-A49 with tachypnoea in 2021, particularly in younger males, though limited by a small sample size and single-centre design. Conclusion: The predominance of RV-A49 in hospitalised children during the SARS-CoV-2 pandemic potentially driven by its replication competence in HNECs and its capacity to enhanced inflammatory responses. The result is hypothesis-generating, warranting further studies with historical strains and broader populations to confirm strain-specific severity.